Neurocrine (NBIX) Biosciences announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia. NBI-1065890 is a next-generation, selective inhibitor of the vesicular monoamine transporter 2. Building on nearly 20 years of deep scientific expertise and experience in VMAT2 inhibition, Neurocrine designed NBI-1065890 to potentially deliver a differentiated profile, including the possibility of longer-acting options for the treatment of TD.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target lowered to $178 from $188 at UBS
- Neurocrine’s Ingrezza capsules show efficacy in involuntary movement disorders
- Neurocrine price target lowered to $177 from $179 at JPMorgan
- Neurocrine price target lowered to $169 from $172 at Truist
- Neurocrine downgraded to Equal Weight from Overweight at Morgan Stanley